ReviewClinical and experimental reproductive medicine2019
Primordial follicle activation as new treatment for primary ovarian insufficiency.
Review in Clinical and experimental reproductive medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 79 citations in OpenAlex.
- Relationship between different modes of death and premature ovarian insufficiency: a literature review.Apoptosis : an international journal on programmed cell death · 2026Review
- Putative "ovarian awakening" in diminished ovarian reserve: a multicenter analysis demonstrates indistinguishability from regression to the mean.Journal of ovarian research · 2026Article
- From Genes to Lives: Integrating the Complexities of Primary Ovarian Insufficiency.International journal of molecular sciences · 2026Review
- Trigonelline activates NRF2 and awakens dormant ovarian follicles to promote pregnancy in aging mice.iScience · 2025Article
- Premature Ovarian Insufficiency and Diminished Ovarian Reserve: From Diagnosis to Current Management and Treatment.Journal of clinical medicine · 2025Review
- Female germline stem cells: recent advances, opportunities, and challenges to overcome.Cell regeneration (London, England) · 2025Review
- Ovarian Mechanobiology: Understanding the Interplay Between Mechanics and Follicular Development.Cells · 2025Review
- Innovations in 3D ovarian and follicle engineering for fertility preservation and restoration.Molecular biology reports · 2024Review
- Dorsomorphin inhibits AMPK, upregulates Wnt and Foxo genes and promotes the activation of dormant follicles.Communications biology · 2024Article
- Ovarian Insufficiency and Fertility Preservation During and After Childhood Cancer Treatment.Journal of adolescent and young adult oncology · 2024Review
- FOXL2 interaction with different binding partners regulates the dynamics of ovarian development.Science advances · 2024Article
- Potential Therapeutic Options for Premature Ovarian Insufficiency: Experimental and Clinical Evidence.Reproductive sciences (Thousand Oaks, Calif.) · 2023Review
- Conventional follicular-phase ovarian stimulation vs. luteal-phase stimulation in suboptimal responders: a randomized controlled trial.F&S reports · 2023Article
- Stem-Cell-Derived Extracellular Vesicles: Unlocking New Possibilities for Treating Diminished Ovarian Reserve and Premature Ovarian Insufficiency.Life (Basel, Switzerland) · 2023Review
- Facilitation of Ovarian Response by Mechanical Force-Latest Insight on Fertility Improvement in Women with Poor Ovarian Response or Primary Ovarian Insufficiency.International journal of molecular sciences · 2023Review
- The mTOR Inhibitor Rapamycin Counteracts Follicle Activation Induced by Ovarian Cryopreservation in Murine Transplantation Models.Medicina (Kaunas, Lithuania) · 2023Article
- HucMSC-EVs Facilitate In Vitro Development of Maternally Aged Preantral Follicles and Oocytes.Stem cell reviews and reports · 2023Article
- Metabolic Mechanisms and Potential Therapeutic Targets for Prevention of Ovarian Aging: Data from Up-to-Date Experimental Studies.International journal of molecular sciences · 2023Review
- Expression of Apoptosis-Related Genes in Cultured Ovarian Tissue of Mouse in Presence of Coenzyme QJournal of family & reproductive health · 2023Article
- Single cell epigenomic and transcriptomic analysis uncovers potential transcription factors regulating mitotic/meiotic switch.Cell death & disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Primordial follicle activation is a process in which individual primordial follicles leave their dormant state and enter a growth phase. While existing hormone stimulation strategies targeted the growing follicles, the remaining dormant primordial follicles were ruled out from clinical use. Recently, in vitro activation (IVA), which is a method for controlling primordial follicle activation, has provided an innovative technology for primary ovarian insufficiency (POI) patients. IVA was developed based on Hippo signaling and phosphatase and tensin homolog (PTEN)/phosphatidylinositol- 3-kinase (PI3K)/protein kinase B (AKT)/forkhead box O3 (FOXO3) signaling modulation. With this method, dormant primordial follicles are activated to enter growth phase and developed into competent oocytes. IVA has been successfully applied in POI patients who only have a few remaining remnant primordial follicles in the ovary, and healthy pregnancies and deliveries have been reported. IVA may also provide a promising option for fertility preservation in cancer patients and prepubertal girls whose fertility preservation choices are limited to tissue cryopreservation. Here, we review the basic mechanisms, translational studies, and current clinical results for IVA. Limitations and further study requirements that could potentially optimize IVA for future use will also be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.